 NEW YORK, May 12, 2021 PRNewswire -- Relmada Therapeutics, Inc. Nasdaq: RLMD, a late-stage biotechnology company addressing diseases of the central nervous system CNS, today provided a corporate update and announced financial results for the first quarter ended March 31, 2021. We continue to advance the development of our lead product candidate, REL-1017, for the treatment of major depressive disorder MDD, said Sergio Traversa, Relmadas Chief Executive Officer. 